
Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

Trastuzumab deruxtecan produces a confirmed objective response rate of 53.8% and 42.9% in the 5.4 mg/kg arm and 6.4 mg/kg treatment arms, respectively, among patients with HER2 mutant non-small cell lung cancer.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.

Research suggests that non-traditional complications from type 2 diabetes are hospitalizing more people now than they did 20 years ago.

Results demonstrated a 64.5% confirmed objective response rate in patients treated with the investigational combination.

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

Prescribers signed a letter expressing concerns about recommendations for restrictions on compounded hormones, which millions of women and other patient populations rely on.

This week, Joanna speaks with Lydia Fenet, ambassador at Christie’s Auction House and best-selling author of The Most Powerful Woman in the Room is You, to discuss the professional side of wellness.

Case report describes severe complications from spontaneous bladder rupture caused by herpes zoster-associated urinary retention.

Asceniv is a plasma-derived polyclonal IVIG drug product designed to prevent serious bacterial infections in patients with primary humoral immunodeficiency disease.

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.

Pharmacy Times spoke with Carina Dolan, PharmD, Editor in Chief of the Pharmacy Market Outlook, about the highlights and the big picture moving forward for hospitals and health systems.

Although OTC medications are generally considered safe when used as directed, there are some key drug interactions for pharmacists to keep in mind when helping patients choose an OTC product.

Hawaii has a distinct culture, and the students said that has led them to have unique perspectives on culturally competent care.

Boehringer Ingelheim’s monoclonal antibody inhibits interleukin-36 (IL-36) signaling and is the first treatment specifically approved for this indication.

Modification is based on phase 3 FIGARO-DKD clinical trial investigating CV and kidney outcomes in more than 13,000 patients with CKD associated with type 2 diabetes.

Surveys show that 70% of migraine sufferers are not satisfied with their current acute treatment regimen.

Decision is based on interim analysis of Pfizer’s GBS6 in healthy pregnant woman aged 18 to 40 years, who were vaccinated during their second or early third trimesters.

Analysis presented at an American Heart Association meeting suggests that following DASH is most effective to reduce the risk of heart attacks and strokes.

Deucravacitinib (Sotyktu) may become the new standard of care oral therapy for moderate-to-severe plaque psoriasis, according to investigators.

Although serotonin is widely associated with feelings of happiness, a study suggests it may be associated with the severity of COVID-19.

Motivational interviewing is a beneficial tool for health care providers to use for improving medication adherence, vaccine hesistancy, and more.

A refundable state-level earned income tax credit was associated with a 21% reduction in high-risk HIV behavior among low-income women last year, suggesting that policy can reduce this burden.

Researchers expect to file for FDA approval within the year following the successful phase 3 trial.

Receiving 3 doses of the COVID-19 vaccine can offer better and more long-lasting protection against the Omicron variant.

Fruquintinib reduced the risk of death in patients with advanced metastatic colorectal cancer by 34% and led to longer overall survival than among those given placebo.

Sunvozertinib is an oral, potent EGFR exon20ins inhibitor with wild-type EGFR selectivity.

But the 2021 modifications to the US Preventive Services Task Force recommendations do not eliminate the inequalities, analysis shows.

The findings also indicate that that treatment may have protective CV and limb benefits for those with kidney failure and concomitant peripheral artery disease.

Viral antigen levels in blood plasma can provide clinically important patient outcomes among hospitalized patients with COVID-19.

Because there is no vaccine for the disease, preventive strategies are needed, investigators from Copenhagen University Hospital in Denmark say.